De Cambra S, Moros A, Barreiro A, Prenafeta A, Madrenas L, Cañete M, Corominas J, Güell I, Prat T, Ferrer L. 

In 2023 COVID-19 cases were mainly associated with BQ.1 and XBB.1.5 Omicron subvariants, causing mostly mild cases and boosting hybrid immunity throughout the population. PHH-1V (HIPRA COVID-19 vaccine) is a bivalent recombinant protein vaccine based on the receptor binding domain of Beta and Alpha SARS-CoV-2 variants, which was authorised for commercialisation in the EU (March 30th, 2023) and UK (July 31st, 2023) as a booster for active immunisation to prevent COVID-19 in individuals ≥16 years of age who have previously received a mRNA vaccine.